Blueprint Medicines announced plans to present detailed results from the registrational PIONEER trial of AYVAKIT, or avapritinib, in indolent systemic mastocytosis, or SM, at the 2023 American Academy of Allergy, Asthma and Immunology, or AAAAI, Annual Meeting, February 24 to 27 in San Antonio. PIONEER data will be featured in two oral platform presentations on Sunday, February 26. One presentation will detail the statistically significant and clinically meaningful results AYVAKIT achieved across the primary and all key secondary endpoints in PIONEER, and a second late-breaking presentation will focus on the impact of AYVAKIT on skin signs and symptoms. An additional PIONEER poster presentation will feature data across a broad set of well-established quality-of-life measures. Blueprint Medicines will share data across 10 presentations, further demonstrating the company’s long-standing scientific leadership position and commitment to SM. Three presentations will focus on PIONEER results while the others will characterize the burden of disease and showcase new approaches to accelerate diagnostic rates, such as by collaborating with medical centers and community networks to generate novel testing algorithms.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BPMC:
- Citi opens ‘negative Catalyst Watch’ on Blueprint Medicines into data
- Blueprint Medicines’ Supplemental NDA for Ayvakit approved by FDA
- Wells Fargo upgrades Blueprint Medicines to Equal Weight with $41 price target
- Blueprint Medicines upgraded to Equal Weight from Underweight at Wells Fargo
- Blueprint Medicines initiated with a Buy at Needham
